- Home
- OCS vs VSTM Comparison
OCS vs VSTM Comparison
Compare OCS & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCS | VSTM |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.4M | 731.8M |
| IPO Year | 2022 | 2011 |
Fundamental Metrics
Financial Performance| Metric | OCS | VSTM |
|---|---|---|
| Price | $8.98 | $8.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $36.37 | $14.67 |
| AVG Volume (30 Days) | 237.8K | ★ 2.0M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | N/A | $276.56 |
| Revenue Next Year | $365.20 | $55.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $8.67 | $3.43 |
| 52 Week High | $34.48 | $10.82 |
Technical Indicators
Market Signals| Indicator | OCS | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 29.65 | 57.95 |
| Support Level | N/A | $7.20 |
| Resistance Level | $10.84 | $8.69 |
| Average True Range (ATR) | 0.53 | 0.44 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 15.38 | 56.90 |
Price Performance
Historical ComparisonAbout OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.